Equities Analysts Issue Forecasts for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities research analysts at Chardan Capital issued their FY2025 earnings per share estimates for Stoke Therapeutics in a note issued to investors on Monday, March 24th. Chardan Capital analyst R. Li expects that the company will post earnings per share of ($1.75) for the year. Chardan Capital has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million.

Other analysts have also issued research reports about the company. Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. HC Wainwright reiterated a "buy" rating and set a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $24.67.

Remove Ads

Stoke Therapeutics Stock Performance

Shares of STOK stock traded down $0.38 on Thursday, hitting $6.83. 250,268 shares of the company's stock traded hands, compared to its average volume of 722,320. The stock has a market capitalization of $369.14 million, a price-to-earnings ratio of -3.27 and a beta of 0.99. The company's fifty day simple moving average is $9.32 and its 200 day simple moving average is $11.13. Stoke Therapeutics has a one year low of $6.72 and a one year high of $17.58.

Institutional Trading of Stoke Therapeutics

Large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System raised its position in Stoke Therapeutics by 16.2% in the fourth quarter. California State Teachers Retirement System now owns 32,068 shares of the company's stock worth $354,000 after acquiring an additional 4,468 shares during the period. Toronto Dominion Bank purchased a new stake in shares of Stoke Therapeutics in the 4th quarter worth $35,001,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock worth $1,053,000 after purchasing an additional 52,813 shares during the period. Squarepoint Ops LLC lifted its position in Stoke Therapeutics by 6.7% during the fourth quarter. Squarepoint Ops LLC now owns 120,242 shares of the company's stock valued at $1,326,000 after purchasing an additional 7,575 shares in the last quarter. Finally, Tang Capital Management LLC bought a new stake in Stoke Therapeutics during the fourth quarter valued at about $3,309,000.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now owns 63,962 shares in the company, valued at $554,550.54. This represents a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is currently owned by corporate insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.